PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-50.78%
R&D reduction while Biotechnology median is 0.00%. Seth Klarman would investigate competitive implications.
-4.70%
G&A reduction while Biotechnology median is 0.00%. Seth Klarman would investigate efficiency gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-40.44%
Operating expenses reduction while Biotechnology median is 3.08%. Seth Klarman would investigate advantages.
-35.51%
Total costs reduction while Biotechnology median is 3.00%. Seth Klarman would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
0.99%
D&A change of 0.99% versus flat Biotechnology D&A. Walter Schloss would verify adequacy.
41.12%
EBITDA change of 41.12% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
40.44%
Income change of 40.44% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
-17.42%
Other expenses reduction while Biotechnology median is -5.18%. Seth Klarman would investigate advantages.
42.50%
Income change of 42.50% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
42.50%
Income change of 42.50% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
40.54%
EPS change of 40.54% versus flat Biotechnology. Walter Schloss would verify quality.
40.54%
Diluted EPS change of 40.54% versus flat Biotechnology. Walter Schloss would verify quality.
0.40%
Share count reduction below 50% of Biotechnology median of 0.06%. Jim Chanos would check for issues.
0.40%
Diluted share reduction below 50% of Biotechnology median of 0.04%. Jim Chanos would check for issues.